UPC APP 34350/2025
—·EP3854403: USE OF SUBSTITUTED AMINOPROPIONATE COMPOUNDS IN TREATMENT OF SARS-COV-2 INFECTION
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieSonstige prozessuale
- Parteien
- Division
- Milan CD
- Richter
- —
- Technology
- Organic Chemistry
- Sprache
- —
- Erste Entscheidung
- 4. Sept. 2025
- 2025-09-04Generic application
Milan Central Division judge-rapporteur issued a procedural order in the revocation action by Gilead Sciences against Academy of Military Medical Sciences (patent EP 3 854 403, Remdesivir for MERS/SARS-CoV-1). The order resolved disputes on the validity of service on the Chinese defendant via its EPO patent representative Lavoix. The court held that service on the patent representative within the CMS was valid under Rule 271(6) RoP. Lavoix's objections to service were inadmissible as the patent representative had no standing to defend the patent holder without a power of attorney. Gilead's premature request for a default judgment was declared currently inadmissible.
Rechtsfragen:Service of proceedings on foreign defendant via EPO patent representative under Rule 271 RoPStanding of patent representative to raise procedural objectionsDefault judgment admissibility under Rule 355/356 RoPValidity of service within vs outside CMS
- EAA9DAF11A1C547DBE32D677B84E5F16_en.pdf2025-09-04EN